Overlap myositis

disease
On this page

Also known as adult-onset overlap myositisnon-specific myositis

Summary

Overlap myositis (MONDO:0016099) is a disease and 1 clinical trial. Top therapeutic interventions include abatacept. A subtype of acquired idiopathic inflammatory myopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Europe)
  • Phenotypes (HPO): 40
  • Clinical trials: 1

Clinical features

Signs & symptoms

Clinical features (HPO)

40 HPO clinical features (Orphanet curated; top 40 by frequency):

HPO IDTermFrequency
HP:0000822HypertensionFrequent (30-79%)
HP:0001369ArthritisFrequent (30-79%)
HP:0002015DysphagiaFrequent (30-79%)
HP:0002960AutoimmunityFrequent (30-79%)
HP:0003119Abnormal circulating lipid concentrationFrequent (30-79%)
HP:0003236Elevated circulating creatine kinase concentrationFrequent (30-79%)
HP:0003493Antinuclear antibody positivityFrequent (30-79%)
HP:0003701Proximal muscle weaknessFrequent (30-79%)
HP:0008997Proximal muscle weakness in upper limbsFrequent (30-79%)
HP:0011838SclerodactylyFrequent (30-79%)
HP:0025131Finger swellingFrequent (30-79%)
HP:0025142Constitutional symptomFrequent (30-79%)
HP:0030859Anti-topoisomerase I antibody positivityFrequent (30-79%)
HP:0030880Raynaud phenomenonFrequent (30-79%)
HP:0032169Severe infectionFrequent (30-79%)
HP:0033040Anti-Sm antibody positivityFrequent (30-79%)
HP:0033555Anti-Ro/SS-A antibody positivityFrequent (30-79%)
HP:0033560Anti-PM-Scl antibody positivityFrequent (30-79%)
HP:0034088Anti-Ku antibody positivityFrequent (30-79%)
HP:0034093Anti-Ro52/TRIM21 antibody positivityFrequent (30-79%)
HP:0100296Perifascicular muscle fiber atrophyFrequent (30-79%)
HP:0000077Abnormality of the kidneyOccasional (5-29%)
HP:0000819Diabetes mellitusOccasional (5-29%)
HP:0001288Gait disturbanceOccasional (5-29%)
HP:0001627Abnormal heart morphologyOccasional (5-29%)
HP:0001873ThrombocytopeniaOccasional (5-29%)
HP:0001882LeukopeniaOccasional (5-29%)
HP:0002092Pulmonary arterial hypertensionOccasional (5-29%)
HP:0002273TetraparesisOccasional (5-29%)
HP:0002725Systemic lupus erythematosusOccasional (5-29%)
HP:0002910Elevated circulating hepatic transaminase concentrationOccasional (5-29%)
HP:0003549Abnormality of connective tissueOccasional (5-29%)
HP:0003551Difficulty climbing stairsOccasional (5-29%)
HP:0004269Subluxation of the small joints of the handOccasional (5-29%)
HP:0006530Abnormal pulmonary interstitial morphologyOccasional (5-29%)
HP:0009053Distal lower limb muscle weaknessOccasional (5-29%)
HP:0009763Limb painOccasional (5-29%)
HP:0011121Abnormal skin morphologyOccasional (5-29%)
HP:0100324SclerodermaOccasional (5-29%)
HP:0001370Rheumatoid arthritisVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameoverlap myositis
Mondo IDMONDO:0016099
Orphanet206572
UMLSC5679784
MedGen1814440
GARD0020352
Is cancer (heuristic)no

Also known as: adult-onset overlap myositis · non-specific myositis

Disease family

This is a subtype of acquired idiopathic inflammatory myopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disordermuscle tissue disorderskeletal muscle disorder › acquired skeletal muscle disease › acquired idiopathic inflammatory myopathyoverlap myositis

Related subtypes (8): eosinophilic fasciitis, immune-mediated necrotizing myopathy, inflammatory myopathy with abundant macrophages, idiopathic eosinophilic myositis, juvenile idiopathic inflammatory myopathy, focal myositis, polymyositis, antisynthetase syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02971683PHASE3COMPLETEDTrial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ABATACEPT41